Amphastar Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

Overall research band Above average

Quality Above average

Valuation Exceptional

Balance sheet Very weak

Market confirmation Strong

One-minute company read

What this report can tell you now

What the company does

Amphastar Pharmaceuticals, Inc., founded in 1996 and headquartered in Rancho Cucamonga, California, is a biopharmaceutical company that develops, manufactures, markets, and distributes both generic and proprietary pharmaceutical products, including injectables, inhalants, and intranasal formulations. Operating through two main segments—Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API)—the company offers a diverse portfolio of medications such as Primatene Mist (an over-the-counter epinephrine inhaler for asthma), Enoxaparin (for deep vein thrombosis), Naloxone (for opioid overdose), emergency Glucagon injection kits, Cortrosyn (for adrenocortical insufficiency diagnosis), Amphadase (a hyaluronidase injection), Epinephrine injections (for allergic reactions), various lidocaine products, Phytonadione injection (Vitamin K1), emergency syringe products, Morphine and Lorazepam injections, Neostigmine methylsulfate injection, and Isoproterenol hydrochloride injection. Amphastar also distributes recombinant human insulin API and porcine insulin API.

The current research profile is Deep Value, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC8.9%Model input; read with the evidence status and period context.

Operating margin19.5%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years13.2%Model input; read with the evidence status and period context.

FCF margin16.8%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.